Cyproheptadine
Periactin (cyproheptadine) is a small molecule pharmaceutical. Cyproheptadine was first approved as Periactin on 1982-01-01. It is used to treat allergic rhinitis perennial, blepharospasm, cluster headache, dyskinesias, and nelson syndrome amongst others in the USA. The pharmaceutical is active against histamine H1 receptor. In addition, it is known to target alpha-1B adrenergic receptor, 5-hydroxytryptamine receptor 6, alpha-1A adrenergic receptor, 5-hydroxytryptamine receptor 7, alpha-1D adrenergic receptor, and histone-lysine N-methyltransferase SETD7.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| respiratory tract diseases | D012140 |
| otorhinolaryngologic diseases | D010038 |
| nervous system diseases | D009422 |
| eye diseases | D005128 |
| skin and connective tissue diseases | D017437 |
| endocrine system diseases | D004700 |
| immune system diseases | D007154 |
| signs and symptoms pathological conditions | D013568 |
| mental disorders | D001523 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cyproheptadine hydrochloride | ANDA | 2023-05-24 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| allergic rhinitis perennial | EFO_1001417 | D012221 | J30.89 |
| blepharospasm | — | D001764 | G24.5 |
| cluster headache | HP_0012199 | D003027 | G44.00 |
| dyskinesias | — | D020820 | G24 |
| nelson syndrome | — | D009347 | E24.1 |
| pruritus | HP_0000989 | D011537 | L29 |
| schizophrenia | EFO_0000692 | D012559 | F20 |
| spastic paraparesis | HP_0002313 | D020336 | — |
| urticaria | EFO_0005531 | D014581 | L50 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CYPROHEPTADINE |
| INN | cyproheptadine |
| Description | Cyproheptadine is the product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia. It has a role as a H1-receptor antagonist, a serotonergic antagonist, an antipruritic drug, an anti-allergic agent and a gastrointestinal drug. It is a member of piperidines and a tertiary amine. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1 |
Target
Alternate
ADRA1B
ADRA1B
HTR6
HTR6
ADRA1A
ADRA1A
HTR7
HTR7
ADRA1D
ADRA1D
SETD7
SETD7
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,696 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more